Actor portrayal

Hand with dab of ZORYVE topical foam in palm
Hand with dab of ZORYVE topical foam in palm

Pivotal Safety

TOLERABLE AND SAFE, FOR ANY LOCATION AND DURATION1,3

WELL-TOLERATED IN TRIAL 203 AND STRATUM STUDIES

  • Not associated with application site pain
  • Not associated with atrophy, striae, dyspigmentation, folliculitis, and/or contact dermatitis
  • In STRATUM, fewer than 1% discontinued ZORYVE foam due to an adverse reaction3

Adverse Reactions Reported in ≥1% of Patients Treated with ZORYVE foam for 8 Weeks1*

ZORYVE FOAM(N=458)Vehicle foam(N=225)NasopharyngitisNausea†Headache7 (1.5%)1 (0.4%)6 (1.3%)0 (0.0%)5 (1.1%)0 (0.0%)
ZORYVE foam(N=458)Vehicle foam(N=225)NasopharyngitisNausea†Headache7 (1.5%)6 (1.3%)5 (1.1%)1 (0.4%)0 (0.0%)0 (0.0%)Adverse Reaction

*Based on pooled safety data from Trial 203 and STRATUM studies. Diarrhea and insomnia were reported in fewer than 1% of patients.

†All incidences of nausea with ZORYVE were mild, the majority were transient and resolved without intervention, and none led to study discontinuation.

OPEN-LABEL LONG-TERM SAFETY STUDY

The adverse reaction profile and efficacy results were consistent with STRATUM for up to 52 weeks of treatment1,4‡

‡A Phase 2, open-label safety trial was conducted in patients (aged ≥ 12 years) with at least moderate seborrheic dermatitis who successfully completed a prior ZORYVE foam trial (n = 133) and in patients naïve to ZORYVE and HYDROARQ TECHNOLOGY™ (n = 267). Patients applied ZORYVE once daily to all active seborrheic dermatitis lesions, including any new lesions that developed during the study, unless otherwise instructed by the investigator, for up to 52 weeks. The primary endpoint was safety. Efficacy measures were included as secondary endpoints and the statistics concluded are descriptive.3

See the Efficacy Data
Explore the
Foam Formulation
Request a Representative